Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin - Japan
doi 10.1248/bpb.b15-00103
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pharmaceutical Society of Japan

Related search

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2019English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Prognostic Value of Tumor Clones Early Reducation in Patients With Chronic Myeloid Leukemia on Nilotinib Treatment Who Failed Imatinib

Hematology & blood transfusion: interdepartamental collection
2016English

Satisfaction With Information on Nilotinib Treatment in Chronic Myeloid Leukemia Patients

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2019English

The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Molecular Monitoring of Therapeutic Milestones and Clinical Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy